A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Key facts

Sponsor

Hutchmed

Principal Investigator

Xiaojun Huang, Doctor

Peking University People's Hospital

Intervention

HMPL-306 Regimen(drug)

Enrollment

316 target

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (30)

• Anhui Provincial Hospital（The First Affiliated Hospital of U STC）, Hefei, Anhui, China
• The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• The Second Hospital of Anhui Medical University, Hefei, Anhui, China
• Peking University People's Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• The First Affilated Hospital of Fujian Medical University, Fuzhou, Fujian, China
• Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
• Guangzhou First People's Hospital, Guangzhou, Guangdong, China
• Nanfang Hospital，Southern Medical University, Guanzhou, Guangdong, China
• Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
• Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06710418
  Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
  University of Washington
• RECRUITINGPHASE3NCT07007312
  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
  Kura Oncology, Inc.
• RECRUITINGPHASE1, PHASE2NCT06928662
  Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1NCT07106749
  CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1NCT06448013
  A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06245746
  UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGNCT06452732
  Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
  Peking University People's Hospital
• RECRUITINGNCT06458257
  The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
  Ruijin Hospital

See all trials for Acute myeloid leukemia with 11q23 abnormalities →